| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-07-06 | Sanofi (France) Walter Reed Army Institute of Research (WRAIR) (USA - MD) | Zika purified inactivated virus (ZPIV) vaccine technology | Zika virus infection | collaboration R&D |
Infectious diseases | Collaboration agreement |
| 2016-07-06 | Moderna Therapeutics (USA - MA) Vertex Pharmaceuticals (USA - MA) | messenger Ribonucleic Acid (mRNA) Therapeutics™ | cystic fibrosis | R&D licensing |
Rare diseases - Genetic diseases | R&D agreement |
| 2016-07-06 | Agenus (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-07-06 | Syndax Pharmaceuticals (USA - MA) UCB (Belgium) | UCB6352 | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-07-05 | Effimune, now OSE Immunotherapeutics (France) Janssen Biotech - J&J (USA) | FR104 | immune-mediated disorders (autoimmune diseases, organ transplantation and graft-versus-host-disease after hematopoietic stem cell transplant) | exercise of an option agreement licensing |
Autoimmune diseases - Immunological diseases - Transplantation | Exercise of an option agreement |
| 2016-07-04 | Novo Nordisk (Denmark) | extension of a production plant | construction of new premises |
Metabolic diseases | Construction of new premises | |
| 2016-07-01 | AstraZeneca (UK) Valeant Pharmaceuticals (Canada) | brodalumab | moderate-to-severe plaque psoriasis, psoriatic arthritis | licensing development commercialisation |
Autoimmune diseases - Dermatological diseases | Licensing agreement |
| 2016-07-01 | Novo Nordisk (Denmark) Aarhus University's Science and Technology faculty (Denmark) | Collaboration agreement | ||||
| 2016-07-01 | AstraZeneca (UK) Leo Pharma (Denmark) | tralokinumab, brodalumab | atopic dermatitis, psoriasis | collaboration licensing |
Autoimmune diseases - Dermatological diseases | Licensing agreement |
| 2016-07-01 | Valneva (France- Austria) | nomination |
Infectious diseases | Nomination | ||
| 2016-07-01 | PCI Biotech (Norway) Curida (Norway) | fimaporfin - disulfonated tetraphenyl chlorin (TPCS2a) (Amphinex™) | production manufacturing |
Cancer - Oncology - Rare diseases | Production agreement | |
| 2016-06-30 | Epigenomics (Germany - USA) | nomination |
Cancer - Oncology - Diagnostic | Nomination | ||
| 2016-06-30 | BMS (USA - NY) PsiOxus Therapeutics (UK) | enadenotucirev and nivolumab | clinical research |
Cancer - Oncology | Clinical research agreement | |
| 2016-06-30 | Atlantic Healthcare (UK) Avecia (USA - OH) | alicaforsen | manufacturing - bioproduction | Technology - Services | Production agreement | |
| 2016-06-29 | CEVEC Pharmaceuticals (Germany) | nomination |
Technology - Services | Nomination | ||
| 2016-06-29 | Moderna Therapeutics (USA - MA) Merck&Co (USA - NJ) | messenger RNA (mRNA)-based personalized cancer vaccines | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2016-06-29 | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) leadXpro (Switzerland) | high-resolution X-ray structures of G protein-coupled receptors (GPCRs) | collaboration |
Technology - Services | Collaboration agreement | |
| 2016-06-29 | Integragen (France) AP-HP The Greater Paris University Hospitals (France) | high-throughput sequencing platform | collaboration development |
Technology - Services | Development agreement | |
| 2016-06-29 | Corvus Pharmaceuticals (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-06-29 | Alder Biopharmaceuticals (USA - WA) | nomination | CNS diseases - Neurological diseases | Nomination |
